MLYS
HEALTHCAREMineralys Therapeutics Inc
$30.12+0.84 (+2.87%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MLYS Today?
No stock-specific AI insight has been generated for MLYS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$12.59$47.65
$30.12
Fundamentals
Market Cap$2.5B
P/E Ratio—
EPS$-2.29
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding82.5M
MLYS News
20 articles- Mineralys Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Mineralys Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Mineralys (MLYS) Q1 2026 Earnings TranscriptMotley Fool·May 6, 2026
- Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 6, 2026
- Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 5, 2026
- Mineralys Therapeutics to Participate in the Bank of America Securities Health Care ConferenceYahoo Finance·May 5, 2026
- Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now?Yahoo Finance·May 3, 2026
- Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026Yahoo Finance·Apr 29, 2026
- Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal OfficerYahoo Finance·Apr 26, 2026
- Does Mineralys Therapeutics’ (MLYS) FDA Progress and Legal Hire Reshape Its Cardiorenal Commercialization Strategy?Yahoo Finance·Apr 7, 2026
- Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?Motley Fool·Apr 7, 2026
- Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of DirectorsYahoo Finance·Apr 6, 2026
- Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat ProgressYahoo Finance·Apr 1, 2026
- Immunic appoints biopharmaceutical executive Jon Congleton to boardProactive Investors·Mar 31, 2026
- Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal OfficerYahoo Finance·Mar 24, 2026
- Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback?Yahoo Finance·Mar 20, 2026
- Mineralys Therapeutics (MLYS) Makes Progress With FDA For HypertensionYahoo Finance·Mar 13, 2026
- Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million InvestmentMotley Fool·Mar 13, 2026
- Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings PlannedMotley Fool·Mar 13, 2026
- Mineralys Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 13, 2026
All 20 articles loaded
Price Data
Open$29.41
Previous Close$29.28
Day High$30.71
Day Low$28.96
52 Week High$47.65
52 Week Low$12.59
52-Week Range
$12.59$47.65
$30.12
Fundamentals
Market Cap$2.5B
P/E Ratio—
EPS$-2.29
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding82.5M
About Mineralys Therapeutics Inc
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—